Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotox...
Saved in:
Main Authors: | Guohao Liu (Author), Yanmei Qiu (Author), Po Zhang (Author), Zirong Chen (Author), Sui Chen (Author), Weida Huang (Author), Baofeng Wang (Author), Xingjiang Yu (Author), Dongsheng Guo (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
by: Wenyong Long, et al.
Published: (2017) -
Diffuse intrinsic pontine glioma: Insights into oncogenesis and opportunities for targeted therapy
by: Andrew Groves, et al.
Published: (2023) -
Oncolytic viral therapy with anti-PD-1 immunotherapy in a pediatric patient with diffuse intrinsic pontine glioma
by: M.P. Osuna Marco, M.D, et al.
Published: (2020) -
Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery
by: Zenab Presswala, et al.
Published: (2024) -
Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: Review of a Single Institution Experience
by: Umberto Tosi, et al.
Published: (2020)